7/26/2021 9:55 am
Date / Time filed with the Register of Regulations 		VA.R. Document Number: R____-______
Virginia Register Publication Information

Transmittal Sheet: Response to Petition for Rulemaking
Initial Agency Notice
X
Agency Decision
Promulgating Board: Board of Optometry
Regulatory Coordinator: Elaine J. Yeatts

(804)367-4688

elaine.yeatts@dhp.virginia.gov
Agency Contact: Leslie L. Knachel

Executive Director

(804)597-4130

leslie.knachel@dhp.virginia.gov
Contact Address: Department of Health Professions

9960 Mayland Drive

Suite 300

Richmond, VA 23233
Chapter Affected:
18 vac 105 - 20: Regulations of the Virginia Board of Optometry
Statutory Authority: State: Chapter 32 of Title 54.1

Federal:
Date Petition Received 05/06/2021
Petitioner Weston Pack
 Petitioner's Request
To add an investigative ophthalmic drop to the approved formulary of drugs that may be prescribed by an optometrist
 Agency Plan
  In accordance with Virginia law, the petition has been filed with the Register of Regulations and will be published on June 7, 2021.  Comment on the petition may be sent by email, regular mail or posted on the Virginia Regulatory Townhall at www.townhall.virginia.gov; comment will be requested until July 7, 2021.    Following receipt of all comments on the petition to amend regulations, the Board will decide whether to make any changes to the regulatory language.  This matter will be on the Board's agenda for its next meeting scheduled for July 16, 2021, and the petitioner will be informed of the Board's decision after that meeting.  
Publication Date 06/07/2021  (comment period will also begin on this date)
Comment End Date 07/07/2021
 Agency Decision
Take no action
Agency Response Date 07/26/2021
 Agency Decision Text
At its meeting on July 16th, the Board voted to deny the petition based on information that the drug requested is not yet approved by the Food & Drug Administration for the particular use in optometric practice. The Board will continue to monitor the process and will consider the initiation of a regulatory process when FDA approval is given.